Skip to content
BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Bio Essence Corp. BIOE

6 fiscal years on record · USD · FY2025 reported · SEC filings only
$1.9M
▲ 485.8% YoY
$896,197

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

The Company’s mission is to provide herbal health, diet, and vitamin nutritional supplements, as explained below. The primary focus of BEP was producing products for BEH and McBE, along with providing original equipment manufacturing and private label services to other companies. BEH targeted and developed traditional Chinese medicines (“TCM”) in the form of single herbs, granules, pills, and tablets. The Company’s operations are now managed through the Company itself, rather than wholly owned entities, for selling the healthy supplement products, and providing OEM services. The Company currently has 4 full-time employees.

Written from the business description in Bio Essence Corp.'s annual report to the U.S. Securities and Exchange Commission, filed 27 March 2026. Every sentence was checked against that document before publication.

Growth

USD 1.9M
Revenue, FY2025 · full 6-year series below
Revenue $M Net income $M
FY2025 · Revenue 1.9 · Net income 0.9
1.0M2.0M-0.5M-1.0M
202020232025
Compound annual growth
+45.1%
+14.6%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +14.6% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2024 · Operating -141.8% · Net -404.0%
-200%-400%
202020222025
ROE

Not applicable: equity was zero or negative in this period, so return on equity has no meaning.

Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on capital employedNot applicable: capital employed was zero or negative in this period, so return on capital employed has no meaning.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2023 · FCF -1.0
-0.5M-1.0M
202020222025

Total assetsUSD 422,474.00
EquityUSD -2.1M
Gross debtUSD 57,482.00
Current ratio0.17×

Equity funds -491% of total assets.

The 6-year record

6 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
BIOE, 6-year financial record
Metric 202520242023202220212020
Revenue $B0.00.00.00.00.00.0
Operating income $B0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B◌−0.0−0.0−0.0−0.0−0.0
Income tax $B0.00.00.00.00.00.0
Net income $B0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B◌◌−0.0−0.0−0.0−0.0
EPS, diluted $◌−0.03−0.03−0.02−0.02−0.02
Dividend / sh $◌◌◌◌◌◌
Payout % — not applicable: no dividend——————
ROE % — not applicable: negative equity——————
Shares out B0.040.040.040.030.030.03

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 30 reconciliationsAUDITED

Reconciled in 6 of the 6 fiscal years we could check. 26 checks were skipped: the balance sheet is not tagged before 2020. 13 checks were skipped: EPS is not tagged before 2020. 13 checks were skipped: revenue is not tagged before 2020.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inCalifornia
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2019

Share this section

Download image